RxDoctor Payments Data

Khamis Shalabi, MD

Internal Medicine · Longview, TXNPI 1124505300

Payments from drug & device makers

$937in general payments, 2019–2025

Across 29 payments — averaging $32.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Inari Medical, Inc.$187
  • Amgen$145
  • E.r. Squibb & Sons, L.L.C.$126
  • Pfizer$78
  • Novo Nordisk$41
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$937 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$118,825
Medicare patients
404
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$112,035
EliquisApixaban66$88,731
TrulicityDulaglutide48$76,306
JardianceEmpagliflozin40$41,074
MounjaroTirzepatide24$23,782
Tresiba Flextouch U-100Insulin Degludec13$7,062
Breo ElliptaFluticasone/Vilanterol16$5,910
SymbicortBudesonide/Formoterol Fumarate22$5,169
Levemir FlexpenInsulin Detemir19$4,092
Atorvastatin Calcium483$3,840
Potassium Chloride159$3,491
SynthroidLevothyroxine Sodium44$3,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,037
Ezetimibe96$2,844
Gabapentin176$2,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$112,03589 claims
Lilly USA, LLCTrulicity, Mounjaro$22$100,08772 claims
PfizerEliquis$78$88,73166 claims
AstraZenecaSymbicort$17$5,16922 claims
AbbVieSynthroid$234$3,25344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →